EyePoint eye drug misses main goal in late-stage trial
EYPT•Late-stage trial misses main goal
Aug. 17 (Reuters) - EyePoint EYPT.O said on Monday its experimental eye drug failed to meet its main goal in a late-stage trial.
Related News
Praxis Precision Medicines, Inc. <PRAX.O>: Raymond James raises target price to $945 from $765
PRAX•
Prairie Operating's Q2 revenue beats estimates on improved drilling performance
PROP•
Alliance Laundry announces secondary offering of 20,500,000 shares by BDT Capital Partners
ALH•
Zenatech sees edge as US Section 232 tariffs hit imported drones up to 100%
ZENA•
Jio-BlackRock to launch regular mutual fund plans through distributors in India
BLK•